WO1993017019A1 - 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist - Google Patents
2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist Download PDFInfo
- Publication number
- WO1993017019A1 WO1993017019A1 PCT/US1993/000880 US9300880W WO9317019A1 WO 1993017019 A1 WO1993017019 A1 WO 1993017019A1 US 9300880 W US9300880 W US 9300880W WO 9317019 A1 WO9317019 A1 WO 9317019A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- treating
- mania
- vomiting
- migraine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Definitions
- This invention relates to 5-chloro-2,3-dihydro-2,2- dimethylbenzofuran-7-carboxylie acid-octahydro-3-hydroxy- 5 2,6-methano-2H-quinolizin-8-yl ester, a novel 5-HT 3 -receptor antagonist, its method of preparation, and to its end-use application in the treatment of conditions responsive to 5-HT 3 receptor antagonism such as radio- and chemo-therapeu ⁇ tically-induced nausea and vomiting, • __ ⁇ « • the treatment of
- the wavy line bonding the oxygen atom of the ester moiety to the 8-position of the octahydro-2,6-methano- 2H-quinolizin moiety indicates that the bonding may be in the endo (trans) or the exo (cis) configuration.
- the preferred configuration is endo.
- the pharmaceutically acceptable acid addition salts referred to above can be non-toxic salts with suitable acids such as those with inorganic acids, for example, hydrochloric, hydrobromic, nitric, sulfuric or phosphoric acids; or with organic acids such as organic carboxylic acids r for example, acetic, propionic, glycolic, maleic, hydroxymaleic, malic, tartaric, citric, salicylic, 2-acetyl- oxybenzoic, nicotinic or isonicotinic; or organic sulfonic acids, for example, methanesulfonic, ethanesulfonic, 2- hydroxyethanesulfonic, 4-toluenesulfonic or 2-naphthalene- sulfonic.
- suitable acids such as those with inorganic acids, for example, hydrochloric, hydrobromic, nitric, sulfuric or phosphoric acids
- organic acids such as organic carboxylic acids r for example, acetic, propi
- Step A' (Alternate to Step A): Using trichlorometh l chloroformate 5-Chloro-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acid trans-octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester
- the racemic mixture can be separated into its separate enantiomers by standard techniques.
- the compounds of the present invention block the M receptors for 5-hydroxytryptamine (5HT) on afferent sensory neurons otherwise known as 5HT 3 -receptors.
- the activity of the compounds of this invention against the 5HT 3 -receptor can be assessed by determining their pA 2 values in the isolated rabbit heart as described by J. R. Fozard et al., Eur. J. Pharmacol. 5£, 195-210 (1979).
- the in ⁇ i ⁇ o 5HT 3 -receptor antagonist activity can be assessed by measurement of the effect of the compound on the Von Bezold- Jarisch reflex induced by 5HT injected intravenously into the rat (see Paintal A. S., Physiol. Rev. 5_3, 159-227 (1973); J. R. Fozard, Naunyn-Schmiedeberg's Arch. Pharmacol. 326, 36-44 (1984).
- the compounds of this invention may be utilized in a variety of treatments.
- the compounds of the present invention are useful in treating conditions responsive to 5-HT 3 receptor antagonism.
- conditions responsive to 5-HT 3 receptor antagonism are well known to those skilled in the art.
- Some examples of these conditions are treating anxiety, psychosis, glaucoma and for stimulating gastric motility (U.S. Patent No. 5,011,846), treatment of panic disorders and/or agoraphobia or obsessive compulsive disorders (Patent No. EP 422,154); treatment of autism or other disorder originating in childhood in which there is mental retardation (Patent No. EP 450,757); treatment of cognitive disorders such as Alzheimer's Disease (U.S. Patent Application Serial No. 806,987); production of orexiogenic effect (U.S. Patent Application Serial No.
- Patent No. GB 2,193,633 Patent No. GB 2,193,633
- Patent No. EP 279,114 and GB 2,206,788 treatment of lung embolism
- Patent No. GB 2,231,265 treatment of cough and/or bronchoconstriction
- Preferred uses for the compounds of the present invention include the treatment of nauseas- and vomiting, particularly radio- and chemo-therapeutically induced in those patients being treated for cancer, in the treatment of pain associated with migraine and neuralgia, in the
- Doses administered to patients are within the range of about 0.01 to about 10 mg per kilogram of body- weight, with 35 0.01 to 1 mg per kilogram of body weight being preferred for parenteral administration and 0.25 to 1 mg per kilogram of body weight upon enteral administration.
- dosage required for the treatment of the foregoing disease states will depend upon such factors as the severity and stage of the particular disease, the age and condition of the patients as such other normal factors taken into consideration by the attending diagnostician.
- patient means warm-blooded animals such as rats, mice, dogs, cats, guinea pigs, primates and humans.
- treat means to prevent or alleviate the patient's disease or condition.
- the compounds of Formula (I) can be administered in various manners to achieve the desired effect.
- the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, lozenges, melts, powders, suspensions, or emulsions.
- Solid unit dosage forms can be capsules of the ordinary gelatin type containing, for example, surfactants, lubricants and inert fillers such as lactose, sucrose, and cornstarch or they can be sustained release preparations.
- the compounds of Formula (I) can be tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders, such as acacia, cornstarch, or gelatin, disintegrating agents such as potato starch or algenic acid, and a lubricant such as stearic acid or magnesium stearate.
- binders such as acacia, cornstarch, or gelatin
- disintegrating agents such as potato starch or algenic acid
- a lubricant such as stearic acid or magnesium stearate.
- Liquid preparations are prepared by dissolving the active ingredient in an aqueous or non- aqueous pharmaceutically acceptable solvent which may also contain suspending agents, sweetening agents, flavoring agents, and preservative agents as are known in the art.
- the compounds may be dissolved in a physiologically acceptable pharmaceutical carrier and administered as either a solution or a suspension.
- suitable pharmaceutical carriers are water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative, or synthetic origin.
- the pharmaceutical carrier may also contain preservatives, buffers, etc. as are known in the art.
- the compounds of this invention can also be administered topically. This can be accomplished by simply preparing a solution of the compound to be administered, preferably using a solvent known to promote transdermal absorption such as ethanol or dimethyl sulfoxide (DMSO) with or without other excipients. Preferably topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety.
- a solvent known to promote transdermal absorption such as ethanol or dimethyl sulfoxide (DMSO)
- DMSO dimethyl sulfoxide
- transdermal devices are described in U.S. Pat. Nos. 3,742,951, 3,797,494, 3,996,934, and 4,031,894 incorporated herein. These devices generally contain a backing member which defines one of its face surfaces, an active agent permeable adhesive layer defining the other face surface and at least one reservoir containing the active agent interposed between the face surfaces.
- the active agent may be contained in a plurality of microcapsules distributed throughout the permeable adhesive layer. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or ucosa of the recipient.
- the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient.
- the encapsulating agent may also function as the membrane.
- the pharmaceutically active compound is contained in a matrix from which it is delivered in the desired gradual, constant and controlled rate.
- the matrix is permeable to the release of the compound through diffusion or microporous flow. The release is rate controlling.
- Such a system, which requires no membrane is described in U.S. Pat. No. 3,921,636 incorporated herein. At least two types of release are possible in these systems. Release by diffusion occurs when the matrix is non-porous.
- the pharmaceutically effective compound dissolves in and diffuses through the matrix itself. Release by microporous flow occurs when the pharmaceutically effective compound is transported through a liquid phase in the pores of the matrix.
- compositions of the present invention are prepared in a manner well known perse in the pharmaceutical art and usually comprise one or more active compounds of the invention in admixture or otherwise in association with a pharmaceutically acceptable carrier or diluent therefor.
- the active ingredient will usually be mixed with a carrier, or diluted by a diluent, or enclosed or encapsulated in a capsule, sachet, cachet, paper or other container.
- a carrier or diluent may be solid, semisolid or liquid material which serves as a vehicle, excipient or medium for the active ingredient. Suitable carriers or diluents are well known per se. See Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, incorporated herein, for a description of the preparation of such formulations.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5514868A JPH07504192A (en) | 1992-02-24 | 1993-02-03 | 2,6-methano-2H-quinolidine derivatives as 5-HT3 receptor antagonists |
KR1019940702945A KR100287933B1 (en) | 1992-02-24 | 1993-02-03 | 2,6-Metano-2H-quinolizine derivatives as 5-HT3-receptor antagonists, methods for their preparation and pharmaceutical compositions comprising the same |
AU36034/93A AU675060B2 (en) | 1992-02-24 | 1993-02-03 | 2,6-methano-2H-quinolizin derivative as 5-HT3-receptor antagonist |
US08/290,792 US5508287A (en) | 1992-02-24 | 1993-02-03 | 2,6-methano-2H-quinolizin derivative as 5-HT3 -receptor antagonist |
EP93904797A EP0628043A1 (en) | 1992-02-24 | 1993-02-03 | 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist |
NO943101A NO943101D0 (en) | 1992-02-24 | 1994-08-23 | 2,6-methano-2H-quinolizine derivative as a 5-HT 3 receptor antagonist |
FI943872A FI105917B (en) | 1992-02-24 | 1994-08-23 | Process for the preparation of a therapeutically active 5-chloro-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acid octahydro-3-hydroxy-2,6-methano-2H-quinolizin-8-yl ester |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92400474.0 | 1992-02-24 | ||
EP92400474 | 1992-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993017019A1 true WO1993017019A1 (en) | 1993-09-02 |
Family
ID=8211614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/000880 WO1993017019A1 (en) | 1992-02-24 | 1993-02-03 | 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0628043A1 (en) |
JP (1) | JPH07504192A (en) |
KR (1) | KR100287933B1 (en) |
AU (1) | AU675060B2 (en) |
CA (1) | CA2130563C (en) |
FI (1) | FI105917B (en) |
HU (1) | HU216831B (en) |
IL (1) | IL104821A (en) |
MX (1) | MX9300948A (en) |
NO (1) | NO943101D0 (en) |
NZ (1) | NZ249346A (en) |
TW (1) | TW226374B (en) |
WO (1) | WO1993017019A1 (en) |
ZA (1) | ZA931146B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6384042B2 (en) | 1999-02-18 | 2002-05-07 | Faerber Lothar | Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662390B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9675602B2 (en) | 2005-03-07 | 2017-06-13 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9717725B2 (en) | 2005-03-07 | 2017-08-01 | The University Of Chicago | Use of opioid antagonists |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0329932A2 (en) * | 1988-02-23 | 1989-08-30 | Merrell Pharmaceuticals Inc. | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments |
EP0517984A1 (en) * | 1991-06-11 | 1992-12-16 | Merrell Dow Pharmaceuticals Inc. | Derivatives of amide analogs of certain methano bridged quinolizines |
-
1993
- 1993-02-03 KR KR1019940702945A patent/KR100287933B1/en not_active IP Right Cessation
- 1993-02-03 JP JP5514868A patent/JPH07504192A/en active Pending
- 1993-02-03 CA CA002130563A patent/CA2130563C/en not_active Expired - Lifetime
- 1993-02-03 WO PCT/US1993/000880 patent/WO1993017019A1/en active IP Right Grant
- 1993-02-03 EP EP93904797A patent/EP0628043A1/en not_active Withdrawn
- 1993-02-03 AU AU36034/93A patent/AU675060B2/en not_active Expired
- 1993-02-03 NZ NZ249346A patent/NZ249346A/en not_active IP Right Cessation
- 1993-02-03 HU HU9402436A patent/HU216831B/en unknown
- 1993-02-18 ZA ZA931146A patent/ZA931146B/en unknown
- 1993-02-19 TW TW082101189A patent/TW226374B/zh not_active IP Right Cessation
- 1993-02-22 MX MX9300948A patent/MX9300948A/en unknown
- 1993-02-22 IL IL10482193A patent/IL104821A/en not_active IP Right Cessation
-
1994
- 1994-08-23 NO NO943101A patent/NO943101D0/en unknown
- 1994-08-23 FI FI943872A patent/FI105917B/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0329932A2 (en) * | 1988-02-23 | 1989-08-30 | Merrell Pharmaceuticals Inc. | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments |
EP0517984A1 (en) * | 1991-06-11 | 1992-12-16 | Merrell Dow Pharmaceuticals Inc. | Derivatives of amide analogs of certain methano bridged quinolizines |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF MEDICINAL CHEMISTRY vol. 35, no. 2, 24 January 1992, WASHINGTON US pages 310 - 319 D.W. ROBERTSON 'Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships' * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6384042B2 (en) | 1999-02-18 | 2002-05-07 | Faerber Lothar | Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662390B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9675602B2 (en) | 2005-03-07 | 2017-06-13 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9717725B2 (en) | 2005-03-07 | 2017-08-01 | The University Of Chicago | Use of opioid antagonists |
Also Published As
Publication number | Publication date |
---|---|
EP0628043A1 (en) | 1994-12-14 |
AU675060B2 (en) | 1997-01-23 |
FI943872A (en) | 1994-08-23 |
NO943101L (en) | 1994-08-23 |
MX9300948A (en) | 1993-08-01 |
CA2130563C (en) | 1997-11-11 |
HU9402436D0 (en) | 1994-10-28 |
CA2130563A1 (en) | 1993-09-02 |
HU216831B (en) | 1999-09-28 |
KR950700297A (en) | 1995-01-16 |
IL104821A0 (en) | 1993-06-10 |
KR100287933B1 (en) | 2001-05-02 |
HUT68249A (en) | 1995-06-28 |
FI105917B (en) | 2000-10-31 |
JPH07504192A (en) | 1995-05-11 |
NZ249346A (en) | 1995-10-26 |
TW226374B (en) | 1994-07-11 |
NO943101D0 (en) | 1994-08-23 |
AU3603493A (en) | 1993-09-13 |
FI943872A0 (en) | 1994-08-23 |
IL104821A (en) | 1997-01-10 |
ZA931146B (en) | 1993-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5011846A (en) | Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof | |
US6908927B2 (en) | Pyridopyranoazepine derivatives, their preparation and their therapeutic application | |
US4906755A (en) | Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds | |
EP0266730B1 (en) | Esters of hexadydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds | |
EP0546181B1 (en) | Indole derivatives and their use as serotonin antagonists | |
EP0518767B1 (en) | Derivatives of amide analogs of certain methano bridged quinolizines | |
US5955470A (en) | Derivatives of amide analogs of certain methano bridged quinolizines | |
IE83573B1 (en) | Derivatives of amide analogs of certain methano bridged quinolizines | |
CA2130563C (en) | 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist | |
US5508287A (en) | 2,6-methano-2H-quinolizin derivative as 5-HT3 -receptor antagonist | |
EP0507637A2 (en) | Use of benzobicyclic carboxamides for the manufacture of a medicament for use as analgesic | |
EP0329932B1 (en) | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments | |
EP0329903A1 (en) | Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of glaucoma | |
US5910501A (en) | Use of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolozin-3(4H)-one and related compounds for treating cognitive disorders | |
EP0329904A1 (en) | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of anxiety | |
EP0329905A1 (en) | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for increasing gastric motility | |
JPH05230057A (en) | Optically active indazole-3-carboxamide derivative and antiemetic agent containing the same as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI HU JP KR NO NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 249346 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08290792 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993904797 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2130563 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 943872 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019940702945 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1993904797 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993904797 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 943872 Country of ref document: FI |